Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

Expanded Phase II Trial of a Carrageenan-Containing Gel for Prevention of HPV Infection

This randomized phase II trial studies how well carrageenan-containing gel (vaginal gel) works in reducing the rate of human papilloma virus (HPV) infection in healthy participants. Carrageenans, which are naturally derived from seaweed, are enhancements to natural lubrication and may be effective in blocking HPV infection.

Study Overview

• Status: Withdrawn
• Conditions: Human Papillomavirus Infection; Healthy Subject
• Intervention / Treatment: Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Drug: carrageenan-containing gel; Other: Placebo

Detailed Description

PRIMARY OBJECTIVES:

I. To measure the overall efficacy of the intervention in reducing the rate of incident cervical HPV infection.

SECONDARY OBJECTIVES:

I. Perform in vitro exploratory testing of how long after vaginal application the drug retains biological activity by collecting cervicovaginal lavage (CVL) at different times and spiking the samples with HPV pseudovirions (PsVs) and measuring PsV entry into target cells.

II. These studies will be expanded to test multiple HPV types and to examine whether the anti-HPV activity of the intervention is preserved in the setting of semen.

III. Store swabs to potentially test candidate biomarkers of microbicide efficacy and safety.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.

ARM II: Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Newark, New Jersey, United States, 07103
      • Rutgers New Jersey Medical School

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 35 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Sexually active women of all ethnicities and races with an intact cervix are eligible for this trial
• Engaging in three or more intercourse events (defined as having penile-vaginal intercourse) per month; subjects must consent not to douche or use any vaginal products, including tampons, for 24 hours before enrollment and study visits
• Normal Pap or Atypical Squamous Cells of Undetermined Significance (ASCUS) Pap test with HPV deoxyribonucleic acid (DNA) negative by reflex testing via Hybrid Capture 2 (Digene Corp., Gaithersburg, MD), a standard clinical assay within clinically acceptable screening guidelines (American Cancer Society [ACS]/American Society for Colposcopy and Cervical Pathology [ASCCP] 2012 Screening Guidelines)
• Using an adequate method of contraception for at least 3 months with no changes and will remain on the contraception for the duration of the trial; an adequate method of contraception is defined as either a hormonal based method (except vaginal rings); an intrauterine device (IUD) (inserted at least 30 days prior to enrollment); female sterilization; or sexual activity with a partner who had a vasectomy
• Speaks either English or Spanish, living in or near Newark with no plans to move in the next year, able to sign consent and complete questionnaires with aid of trained personnel

Exclusion Criteria:

• Prior use of an HPV vaccine

  • Women in the vaccine-eligible age range cannot have received vaccine prior to enrollment, but will be offered HPV vaccination at the end of the study; in brief, we are interested in the efficacy of intervention in preventing HPV in the absence of HPV vaccination, since most women worldwide who might utilize intervention will not have been vaccinated; this includes United States (US) women in the vaccine "catch-up" 19-26 year old age group (beyond the age groups eligible for Vaccines for Children- funded vaccination) who have so far had very low (< 10%) vaccine uptake; it also includes the entire group of US women > 26 years of age; moreover, it includes women of all ages in developing countries, who most need an HPV prevention strategy, but may never be vaccinated; it should be noted that delaying vaccination in women 19-26 years of age by one year is safe and reasonable, since there is insufficient data to establish a recommendation for or against universal vaccination in this age group as concluded by an American Cancer Society expert panel, which includes the Principal Investigator (PI) of this protocol, Dr. Mark Einstein; it is anticipated that if the intervention gel is efficacious, HPV vaccinated women would need to be studied in a similar future trial with power analysis taking into account vaccine effectiveness as well
• Any previous surgical excision of cervical intraepithelial neoplasia (CIN) or hysterectomy
• A serious, concomitant disorder, including active systemic infection requiring treatment
• Prior history of or current malignancy other than adequately treated skin cancer (squamous cell cancer or basal cell carcinoma)
• Documented or suspected immunosuppressive disorder or autoimmune disease
• Any significant cardiac, hepatic or renal disease
• Pregnant and/or breast-feeding

• Recent (within 4 weeks of screening) or concomitant long term treatment with systemic steroids, immunosuppressive/immunomodulating drugs (e.g. cyclosporine, corticosteroids)

  • Intranasal, inhaled and/or topical steroids are permissible
• Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment
• Active genital ulcers
• Use of an investigational drug in the 3 months prior to screening and must agree to not participate in any drug or device study while enrolled in this study
• Any known allergy or hypersensitivity to vaginal lubricants or any component of study product

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I (carrageenan-containing gel); Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.	Other: Laboratory Biomarker Analysis; Correlative studies; Other: Questionnaire Administration; Ancillary studies; Drug: carrageenan-containing gel; Applied vaginally; Other Names: Divine 9 with Carragel
Placebo Comparator: Arm II (placebo gel); Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.	Other: Laboratory Biomarker Analysis; Correlative studies; Other: Questionnaire Administration; Ancillary studies; Other: Placebo; Applied vaginally; Other Names: PLCB

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of incident cervical HPV infection	The primary analysis will be based upon the intent to treat approach. The cumulative incidence of HPV infection for each treatment group will be estimated as described above and the percent reduction in incidence due to intervention will be computed along with the corresponding one-sided 80% lower confidence bound.	Up to 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative incidence rates of HPV in the target population (using data from the placebo group)	Multivariate logistic regression models that incorporate additional subject data (e.g., frequency of intercourse and number of recent sex partners, anal sex, and smoking behavior) will be fit to the data to control for potential imbalances in subject characteristics that may occur despite randomization with HPV infection status as the binary dependent variable. A generalized estimating equation approach will also be used to model treatment effect on infection with multiple HPV types.	At 1 year
Subject adherence as measured by monthly applicator collection and counting	Will perform a per protocol analysis including only "adherent" subjects, defined as subjects who report gel use as recommended (within one hour of intercourse) in > 50% of all vaginal intercourse acts. Will perform additional analyses to identify any imbalances in subject characteristics across groups, and in secondary analyses using logistic regression models to incorporate this as above.	Up to 1 year
Behavioral characteristics assessed by questionnaires	Multivariate logistic regression models that incorporate additional subject data (e.g., frequency of intercourse and number of recent sex partners, anal sex, and smoking behavior) will be fit to the data to control for potential imbalances in subject characteristics that may occur despite randomization with HPV infection status as the binary dependent variable. A generalized estimating equation approach will also be used to model treatment effect on infection with multiple HPV types.	Up to 1 year
Biological activity of carrageenan-containing gel or placebo as measured by CVL at different times and spiking the samples with HPV PsVs and measuring PsV entry into target cells	Changes in this variable at each time point relative to baseline will be compared between groups using analysis of covariance models to adjust for baseline level. In addition, linear mixed effects models will be fit to all the repeated measurements to evaluate and compare trends over time while adjusting for the within-subject correlation in the data.	Baseline to up to 12 months

Collaborators and Investigators

• Sponsor: Rutgers, The State University of New Jersey
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Mark Einstein, Rutgers University

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2016
• Primary Completion (Actual): February 13, 2019
• Study Completion (Actual): February 13, 2019

Study Registration Dates

• First Submitted: February 26, 2015
• First Submitted That Met QC Criteria: March 3, 2015
• First Posted (Estimate): March 6, 2015

Study Record Updates

• Last Update Posted (Actual): August 1, 2019
• Last Update Submitted That Met QC Criteria: July 30, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Virus Diseases; Disease Attributes; DNA Virus Infections; Tumor Virus Infections; Infections; Communicable Diseases; Papillomavirus Infections
• Other Study ID Numbers: 20150002694 (Other Identifier: Rutgers New Jersey Medical School); P30CA013330 (U.S. NIH Grant/Contract); NCI-2015-00209 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); R01CA148966 (U.S. NIH Grant/Contract)